Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State

JAMA - Journal of the American Medical Association

Volumn 323, Issue 24, 2020, Pages 2493-2502

  Rosenberg, Eli S ^a   Dufort, Elizabeth M ^b   Udo, Tomoko ^a   Wilberschied, Larissa A ^b   Kumar, Jessica ^b   Tesoriero, James ^b   Weinberg, Patti ^c   Kirkwood, James ^b   Muse, Alison ^b   Dehovitz, Jack ^c,d   Blog, Debra S ^b   Hutton, Brad ^b   Holtgrave, David R ^a   Zucker, Howard A ^b  

^a UNIVERSITY AT ALBANY   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c IPRO Inc   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZITHROMYCIN; HYDROXYCHLOROQUINE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL OUTCOME; COHORT ANALYSIS; CORONAVIRUS DISEASE 2019; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; NEW YORK; OXYGEN SATURATION; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; BETACORONAVIRUS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; MORTALITY; MULTICENTER STUDY; PANDEMIC; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; VIRUS PNEUMONIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; ARRHYTHMIAS, CARDIAC; AZITHROMYCIN; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEART ARREST; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDROXYCHLOROQUINE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK; PANDEMICS; PNEUMONIA, VIRAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85084700639     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.8630     Document Type: Article

References (32)

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395 (10223): 470-473. doi: 10.1016/S0140-6736(20)30185-9 31986257
2. The Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 dashboard. 2020. Accessed March 24, 2020. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd402994234 67b48e9ecf6
3. Rosenberg ES, Dufort EM, Blog DS, COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State-March 2020. Clin Infect Dis. Published online May 8, 2020. doi: 10.1093/cid/ciaa549
4. New York State Department of Health. COVID-19 Tracker. 2020. Accessed May 7, 2020. https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n
5. Liu J, Cao R, Xu M, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6 (1): 16. doi: 10.1038/s41421-020-0156-0 32194981
6. Yao X, Ye F, Zhang M, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; ciaa237. doi: 10.1093/cid/ciaa237 32150618
7. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 55 (4): 105932. doi: 10.1016/j.ijantimicag.2020.105932 32145363
8. Gautret P, Lagier JC, Parola P, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020: 105949. doi: 10.1016/j.ijantimicag.2020.105949 32205204
9. Chen Z, Hu J, Zhang Z, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. Preprint posted April 10, 2020. doi: 10.1101/2020.03.22.20040758
10. McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018; 36 (4): 545-551. 29652656
11. Hung YM, Wang YH, Lin L, Wang PYP, Chiou JY, Wei JC. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. Int J Clin Pract. 2018; 72 (5): e13095. doi: 10.1111/ijcp.13095 29691971
12. Chorin E, Dai M, Shulman E, The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. Published online April 24, 2020. doi: 10.1038/s41591-020-0888-2
13. Borba MGS, Val FFA, Sampaio VS, Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020; 3 (4): e208857. doi: 10.1001/jamanetworkopen.2020.8857
14. FDA. Fact sheet for health care providers: emergency use authorization (EUA) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. Posted April 27, 2020. Accessed May 7, 2020. https://www.fda.gov/media/136537/download
15. Garg S, Kim L, Whitaker M, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (15): 458-464. doi: 10.15585/mmwr.mm6915e3 32298251
16. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (13): 382-386. doi: 10.15585/mmwr.mm6913e2 32240123
17. Magagnoli J, Narendran S, Pereira F, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. Preprint posted April 23, 2020. doi: 10.1101/2020.04.16.20065920
18. Goyal P, Choi JJ, Pinheiro LC, Clinical characteristics of Covid-19 in New York City. N Engl J Med. Published online April 17, 2020. doi: 10.1056/NEJMc2010419 32302078
19. Petrilli CM, Jones SA, Yang J, Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. Preprint posted April 11, 2020. doi: 10.1101/2020.04.08.20057794
20. Davis CE, Hyde JE, Bangdiwala SI, Nelson JJ. An example of dependencies among variables in a conditional logistic regression. In: Modern Statistical Methods in Chronic Disease Epidemiology. John Wiley & Sons; 1986:140-147.
21. Lin DY, Wei LJ. The Robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989; 84 (408): 1074-1078. doi: 10.1080/01621459.1989.10478874
22. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017; 167 (4): 268-274. doi: 10.7326/M16-2607 28693043
23. Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. Preprint posted April 14, 2020. doi: 10.1101/2020.04.10.20060699
24. Geleris J, Sun Y, Platt J, Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. Published online May 7, 2020. doi: 10.1056/NEJMoa2012410 32379955
25. Gorgels APM, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJJ. Out-of-hospital cardiac arrest: the relevance of heart failure. Eur Heart J. 2003; 24 (13): 1204-1209. doi: 10.1016/S0195-668X(03)00191-X 12831814
26. Low LS, Kern KB. Importance of coronary artery disease in sudden cardiac death. J Am Heart Assoc. 2014; 3 (5): e001339. doi: 10.1161/JAHA.114.001339 25288614
27. Richardson S, Hirsch JS, Narasimhan M,; and the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. Published online April 22, 2020. doi: 10.1001/jama.2020.6775 32320003
28. Zhou F, Yu T, Du R, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3 32171076
29. Yancy CW. COVID-19 and African Americans. JAMA. Published online April 15, 2020. doi: 10.1001/jama.2020.6548 32293639
30. NIH. COVID-19 treatment guidelines. Accessed April 24, 2020. https://covid19treatmentguidelines.nih.gov/introduction/
31. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Posted April 11, 2020. Accessed April 24, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
32. FDA Drug Safety Communication. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. Posted April 24, 2020. Accessed May 8, 2020. https://www.fda.gov/media/137250/download